Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.46 |
| ▸ | GABRP | O00591 | 6/20 | 0.46 |
| ▸ | GABRD | O14764 | 6/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.46 |
| ▸ | GABRE | P78334 | 6/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.46 |
| ▸ | CDC7 | O00311 | 5/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9602508 | 0.88 | CYP4F2 (0.47) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7008579 | 0.86 | CYP1A2 (0.47) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL128612 | 0.86 | CYP1A2 (0.47) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL480291 | 0.86 | CYP4F2 (0.52) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL20357239 | 0.84 | CYP1A2 (0.46) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29479667 | 0.83 | PARP1 (0.50) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL502256 | 0.83 | PARP1 (0.50) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4710257 | 0.83 | JMJD6 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL744204 | 0.83 | GABRA1 (0.43) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL743703 | 0.82 | CYP1A2 (0.44) | CYP1A2GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Selder Pharma Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Selder Pharma Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9526719-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526719-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| CN-1205694-A | Quinazoline derivatives | ZENECA LTD (GB) | 1999-01-20 | — | — | CN | disclosed |
| US-5217963-A | Antiischemic, antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| US-5057506-A | Anticonvulsants, antispasmodic and antischemic agents | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| US-4906621-A | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | CIBA-GEIGY CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | CYP1A2 2702/4885GABRA1 99/4885GABRG2 95/4885 |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | BRS3, BDKRB2, NTSR2 | CYP1A2 2702/4885GABRA1 99/4885GABRG2 95/4885 |
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | CYP1A2 2702/4885GABRA1 99/4885GABRG2 95/4885 |
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | CYP1A2 516/4885GABRA1 1614/4885GABRG2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.